A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.
Inclusion Criteria:
Exclusion Criteria:
Nashua, New Hampshire 03060, United States
Brampton, L6T 0G1, Canada
Kelowna, V1Y 1Z9, Canada
Mississauga, L4Y 2N8, Canada
Montreal, H3A 2B4, Canada
Ottawa, K2G 6E2, Canada
Sherbrooke, J1H1Z1, Canada
Toronto, M9W 4L6, Canada
Vancouver, V6Z 2E8, Canada
Waterloo, N2J 1C4, Canada